RISCA:SCA1、SCA2、SCA3、SCA6、SCA7 风险个体的前瞻性研究 (RISCA)
脊髓小脑性共济失调 1 型、2 型、3 型、6 型和 7 型(SCA1、SCA2、SCA3、SCA6、SCA7)风险个体的前瞻性研究
脊髓小脑性共济失调 (SCAs) 是一组临床和遗传异质性常染色体显性遗传的进行性共济失调疾病。 据估计,欧洲共同体中有 30,000 人直接来自受 SCA 疾病影响的个体,因此有 50% 的风险遗传了 SCA 突变。 这些处于危险中的个体提供了一个独特的研究机会,可以前瞻性地研究 SCA 疾病的症状前阶段,并确定最早和最敏感的临床体征和预示疾病发作的生物标志物。 该信息对于开发旨在推迟共济失调临床发作的未来治疗干预措施至关重要。
因此,我们建议对处于最常见 SCA 疾病、SCA1、SCA2、SCA3 和 SCA6 (RISCA) 风险中的个体进行前瞻性观察研究。 我们的目的是回答以下问题:(1)突变携带者疾病表现的发生率是多少? (2) 在 SCA1、SCA2、SCA3 和 SCA6 中,哪些临床症状先于显性共济失调发作? (3) 前兆的患病率和发生率如何? (4) 前兆的患病率和发生率是否受基因型、性别、年龄、疾病表现的估计时间和重复长度的影响? (5) 某些前兆的存在是否预示着共济失调的表现? (6) 是否存在共济失调发作前的 MRI 改变? 计划招募 480 名研究参与者,并在六年内定期跟踪他们。 每次访问时,研究参与者都会在结构化访谈中被问及一些可能先于共济失调发作的预定义临床体征。 此外,还将应用以下自我评估量表:匹兹堡睡眠质量指数 (PSQI)、不宁腿综合征诊断标准、患者健康问卷 (PHQ-9)。 所有研究参与者都将接受身体检查,包括共济失调评估和评级量表 (SARA)。 研究参与者将进一步执行 SCA 功能组合 (SCA-FC),这是一种基于与步态(8 米计时步行)、言语(PATA 速率)和手部功能(9 孔钉板)相关的定量测试结果的功能能力综合测量. 在一部分研究参与者中,我们将记录眼球运动并获得体积 MRI。 该研究还将用于收集和储存血液和尿液样本,用于蛋白质组学和基因表达研究。
RISCA 由共济失调研究小组 (ASG) 进行。 它依赖于 EUROSCA 项目创建的网络结构。
研究概览
地位
条件
研究类型
注册 (实际的)
联系人和位置
学习地点
-
-
-
Paris、法国、75013
- Pitié Salpetrière Hospital
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
取样方法
研究人群
描述
纳入标准:
- 有患脊髓小脑性共济失调 1 型、2 型、3 型、6 型和 7 型(SCA1、SCA2、SCA3、SCA6 和 SCA7)风险的个体
- SCA1、SCA2、SCA3 或 SCA7 年龄在 18 至 50 岁之间
- SCA6 年龄在 35 至 70 岁之间
- 无共济失调的临床体征(SARA < 3)
排除标准:
- 没有书面同意
- 没有家庭成员受到影响
- 存在共济失调的临床症状(SARA > 3)
学习计划
研究是如何设计的?
设计细节
- 观测模型:以家庭为基础
- 时间观点:预期
队列和干预
团体/队列 |
|---|
|
症状前携带者
|
|
非携带者亲属
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Determination of the incidence rate of ataxia onset among mutation carriers
大体时间:Day 0
|
Blood sample for a genetic test.
Identification of individuals carrying a mutation for SCA types 1, 2, 3, 6, and 7
|
Day 0
|
|
Confidence Rating for Ataxia Assessment
大体时间:Day 0, Month 24, Month 48, Month 72
|
The invetigator must specify the degree of confidence in the presence of specific signs that may be associated with SCA ataxia .
90-100 % : investigator very confident in the diagnosis of ataxia, 70-89 % : high confidence, but with some uncertainty, 50-69 % : moderate confidence, <50 % : significant uncertainty.
|
Day 0, Month 24, Month 48, Month 72
|
|
INAS scoring in ataxia (Inventory of Non-Ataxia Signs)
大体时间:Day 0, Month 24, Month 48, Month 72
|
Score range 0-16.
0 : No nonataxia signsdetected.
Higher score : more non-ataxia neurological signs are present
|
Day 0, Month 24, Month 48, Month 72
|
|
Assessmet of sleep quality in ataxia : PSQI (Pittsburg Sleep Quality Index)
大体时间:Day 0, Month 24, Month 48, Month 72
|
The global PSQI score ranges from 0 to 21. 0-5 : good sleep quality.
>5 : Poor sleep quality / clinically significant slep disturbance.
Higher scores : worse sleep quality
|
Day 0, Month 24, Month 48, Month 72
|
|
Restless Legs Syndrome (RLS) assessment in Ataxia
大体时间:Day 0, Month 24, Month 48, Month 72
|
Total Score : 0-40 0 : No RLS symptoms, 1-10 : Mild, 11-20 : Moderate, 21-30 : Severe, 31-40 : Very severe.
|
Day 0, Month 24, Month 48, Month 72
|
|
Assessment of depression by Patient's Health Questionnaire PHQ-9
大体时间:Day 0, Month 24, Month 48, Month 72
|
Used to evaluatethe severity of depressive symptoms, giving a total score rangong from 0 to 27. 0-4 : minimal or no deprssive symptoms, 5-9 : mild depression, 10-14 : moderate depression, 15-19 : moderately severe depression, 20-27 : severe depression
|
Day 0, Month 24, Month 48, Month 72
|
|
Assessment of the disease's impact on quality of life based on EQ-5D index (EuroQoL-5 Dimensions)
大体时间:Day 0, Month 24, Month 48, Month 72
|
It generally ranges from less than 0 to 1 (perfect health).
Higher scores indicate a better quality of life
|
Day 0, Month 24, Month 48, Month 72
|
|
Assessment and Rating of Ataxia
大体时间:Day 0, Month 24, Month 48, Month 72
|
SARA (Scale of Assessment and Rating Ataxia) is an 8-item performance based scale, yielding a total score of 0 (no ataxia) to 40 (most severe ataxia).
|
Day 0, Month 24, Month 48, Month 72
|
|
Functional assessment of the severity of ataxia
大体时间:Day 0, Month 24, Month 48, Month 72
|
Using CCFS (Composite Cerebellar Functional Severity Score) method for assessing cerebellar ataxia across a wide range of severity.
=0,85 : average value in an individual without ataxia.
0,90-1,00 : very mild or early-stage cerebellar impairment.
1,00-1,20 : Mild to moderate cerebellar impairment.
>1,2 : More pronounced cerebellar impairment.
|
Day 0, Month 24, Month 48, Month 72
|
|
Upper Limb motor coordination assessment
大体时间:Day 0, Month 24, Month 48, Month 72
|
A device equipped with a pre-calibrated force sensor that measures grip strength and lifting capacity, and a Polhemus 3D position sensor that measures position along the -x, -y, and -z axes and the object's orientation to assess movement.
Grip force variability coefficient is calculated : Lowe % (more stable greap force control) - Higher % (greater variability and poorer motor coordination)
|
Day 0, Month 24, Month 48, Month 72
|
|
Finger tapping assessment
大体时间:Day 0, Month 24, Month 48, Month 72
|
Number of taps within 10 seconds (higher = better)
|
Day 0, Month 24, Month 48, Month 72
|
|
GAITRite in an ataxia assessment
大体时间:Day 0, Month 24, Month 48, Month 72
|
The participant walks along a carpet equipped with sensors that record the time it takes to make a step as well as the position of the feet.
|
Day 0, Month 24, Month 48, Month 72
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Functional performance assessment by 8MW test (8 meters walking time)
大体时间:Day 0, Month 24, Month 48, Month 72
|
Measure in seconds, the time needed to cover a distance of 8 meters as quickly and safely as possible
|
Day 0, Month 24, Month 48, Month 72
|
|
Functional performance assessment by 9HPT : Nine Hole Peg Test
大体时间:Day 0, Month 24, Month 48, Month 72
|
The test consists of insertingand removing 9 wooden pegs from a board as quickly as possible, using only one hand.
A healthy adult completes the test in about 10 to 20 seconds.
|
Day 0, Month 24, Month 48, Month 72
|
|
Functional performance assessment by by PATA
大体时间:Day 0, Month 24, Month 48, Month 72
|
It involves counting the number of clear répétitions of the syllable or sentence " pa-ta " that a patient can produce in 10 seconds
|
Day 0, Month 24, Month 48, Month 72
|
|
Assessment of retinal thickness
大体时间:Day 0, Month 24, Month 48, Month 72
|
By using Optical Coherence Tomography (OCT) scan
|
Day 0, Month 24, Month 48, Month 72
|
|
Identification of slow saccades during eye tracking
大体时间:Day 0, Month 24, Month 48, Month 72
|
By recording of eye movements
|
Day 0, Month 24, Month 48, Month 72
|
|
Evaluation of the functional connectivity
大体时间:Day 0, Month 72
|
Brain imaging will help determine whether functional connectivity between the cortex and the cerebellum is impaired
|
Day 0, Month 72
|
合作者和调查者
出版物和有用的链接
一般刊物
- Wilke C, Haas E, Reetz K, Faber J, Garcia-Moreno H, Santana MM, van de Warrenburg B, Hengel H, Lima M, Filla A, Durr A, Melegh B, Masciullo M, Infante J, Giunti P, Neumann M, de Vries J, Pereira de Almeida L, Rakowicz M, Jacobi H, Schule R, Kaeser SA, Kuhle J, Klockgether T, Schols L; SCA3 neurofilament study group; Barro C, Hubener-Schmid J, Synofzik M. Neurofilaments in spinocerebellar ataxia type 3: blood biomarkers at the preataxic and ataxic stage in humans and mice. EMBO Mol Med. 2020 Jul 7;12(7):e11803. doi: 10.15252/emmm.201911803. Epub 2020 Jun 8.
- Jacobi H, du Montcel ST, Romanzetti S, Harmuth F, Mariotti C, Nanetti L, Rakowicz M, Makowicz G, Durr A, Monin ML, Filla A, Roca A, Schols L, Hengel H, Infante J, Kang JS, Timmann D, Casali C, Masciullo M, Baliko L, Melegh B, Nachbauer W, Burk-Gergs K, Schulz JB, Riess O, Reetz K, Klockgether T. Conversion of individuals at risk for spinocerebellar ataxia types 1, 2, 3, and 6 to manifest ataxia (RISCA): a longitudinal cohort study. Lancet Neurol. 2020 Sep;19(9):738-747. doi: 10.1016/S1474-4422(20)30235-0.
- Wilke C, Mengel D, Schols L, Hengel H, Rakowicz M, Klockgether T, Durr A, Filla A, Melegh B, Schule R, Reetz K, Jacobi H, Synofzik M. Levels of Neurofilament Light at the Preataxic and Ataxic Stages of Spinocerebellar Ataxia Type 1. Neurology. 2022 May 17;98(20):e1985-e1996. doi: 10.1212/WNL.0000000000200257. Epub 2022 Mar 9.
- Jacobi H, Reetz K, du Montcel ST, Bauer P, Mariotti C, Nanetti L, Rakowicz M, Sulek A, Durr A, Charles P, Filla A, Antenora A, Schols L, Schicks J, Infante J, Kang JS, Timmann D, Di Fabio R, Masciullo M, Baliko L, Melegh B, Boesch S, Burk K, Peltz A, Schulz JB, Dufaure-Gare I, Klockgether T. Biological and clinical characteristics of individuals at risk for spinocerebellar ataxia types 1, 2, 3, and 6 in the longitudinal RISCA study: analysis of baseline data. Lancet Neurol. 2013 Jul;12(7):650-8. doi: 10.1016/S1474-4422(13)70104-2. Epub 2013 May 22.
- Tezenas du Montcel S, Durr A, Rakowicz M, Nanetti L, Charles P, Sulek A, Mariotti C, Rola R, Schols L, Bauer P, Dufaure-Gare I, Jacobi H, Forlani S, Schmitz-Hubsch T, Filla A, Timmann D, van de Warrenburg BP, Marelli C, Kang JS, Giunti P, Cook A, Baliko L, Melegh B, Boesch S, Szymanski S, Berciano J, Infante J, Buerk K, Masciullo M, Di Fabio R, Depondt C, Ratka S, Stevanin G, Klockgether T, Brice A, Golmard JL. Prediction of the age at onset in spinocerebellar ataxia type 1, 2, 3 and 6. J Med Genet. 2014 Jul;51(7):479-86. doi: 10.1136/jmedgenet-2013-102200. Epub 2014 Apr 29.
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.